237 related articles for article (PubMed ID: 18677288)
1. Does the preventive effect of different drugs depend on location of the atherosclerotic process?
Poredos P; Jezovnik MK
Int Angiol; 2008 Aug; 27(4):274-80. PubMed ID: 18677288
[TBL] [Abstract][Full Text] [Related]
2. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
3. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events.
Coppola G; Novo S
Arch Med Res; 2007 Jul; 38(5):479-88. PubMed ID: 17560452
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
Blinc A; Poredos P
Eur J Clin Invest; 2007 Mar; 37(3):157-64. PubMed ID: 17359482
[TBL] [Abstract][Full Text] [Related]
5. Optimal risk factor modification and medical management of the patient with peripheral arterial disease.
Chi YW; Jaff MR
Catheter Cardiovasc Interv; 2008 Mar; 71(4):475-89. PubMed ID: 18307227
[TBL] [Abstract][Full Text] [Related]
6. Re: Secondary medical prevention in patients with peripheral arterial disease.
Schouten O; Welten GM; Bax JJ; Poldermans D
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
[No Abstract] [Full Text] [Related]
7. Peripheral arterial disease: a review of disease awareness and management.
Watson K; Watson BD; Pater KS
Am J Geriatr Pharmacother; 2006 Dec; 4(4):365-79. PubMed ID: 17296541
[TBL] [Abstract][Full Text] [Related]
8. Secondary prevention of arterial disease in very elderly people: results from a prospective registry (FRENA).
López-Jiménez L; Camafort M; Tiberio G; Carmona JA; Guijarro C; Martínez-Peñalver F; Monreal M;
Angiology; 2008; 59(4):427-34. PubMed ID: 18388061
[TBL] [Abstract][Full Text] [Related]
9. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
[TBL] [Abstract][Full Text] [Related]
10. Supporting a call to action for peripheral artery disease: insights from two prospective clinical registries.
Hackam DG; Tan MK; Lin PJ; Mehta PG; Jaffer S; Kates M; Oh M; Grima EA; Langer A; Goodman SG; ;
J Vasc Surg; 2006 Oct; 44(4):776-81. PubMed ID: 16930931
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?
Heeneman S; Donners MM; Bai L; Daemen MJ
Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):345-64. PubMed ID: 17338677
[TBL] [Abstract][Full Text] [Related]
12. [The best of vascular medicine in 2006].
Mounier-Vehier C; Stephan D; Aboyans V; Beregi JP; Lacroix P; Léger P; Long A; Sevestre MA;
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():47-55. PubMed ID: 17405565
[TBL] [Abstract][Full Text] [Related]
13. Have statins changed the natural history of atheromatous disease and its treatment?
Samson RH
Semin Vasc Surg; 2008 Sep; 21(3):160-4. PubMed ID: 18774452
[TBL] [Abstract][Full Text] [Related]
14. Office management of peripheral arterial disease.
Aronow WS
Am J Med; 2010 Sep; 123(9):790-2. PubMed ID: 20800143
[TBL] [Abstract][Full Text] [Related]
15. A new way of targeting to treat coronary artery disease.
Siu D
J Cardiovasc Med (Hagerstown); 2010 Jan; 11(1):1-6. PubMed ID: 19829140
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation.
Bianchi C; Montalvo V; Ou HW; Bishop V; Abou-Zamzam AM
Ann Vasc Surg; 2007 Mar; 21(2):163-6. PubMed ID: 17349357
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis in Israel.
Barski L; Porath A; Novack V; Jotkowitz A
Isr Med Assoc J; 2007 May; 9(5):376-9. PubMed ID: 17591377
[TBL] [Abstract][Full Text] [Related]
18. Should all patients with peripheral arterial disease be treated with an angiotensin-converting enzyme inhibitor?
Al-Omran M; Lindsay TF
Can J Cardiol; 2005 Feb; 21(2):189-93. PubMed ID: 15729421
[TBL] [Abstract][Full Text] [Related]
19. Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study.
Al-Omran M; Mamdani MM; Lindsay TF; Melo M; Juurlink DN; Verma S;
J Vasc Surg; 2008 Sep; 48(3):607-12. PubMed ID: 18585886
[TBL] [Abstract][Full Text] [Related]
20. Systemic antiatherosclerotic treatment for the peripheral arterial occlusive disease patient.
Baumgartner I
Expert Opin Pharmacother; 2005 Oct; 6(13):2181-92. PubMed ID: 16218880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
